These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2546 related items for PubMed ID: 30809081

  • 1. Relationships among KRAS mutation status, expression of RAS pathway signaling molecules, and clinicopathological features and prognosis of patients with colorectal cancer.
    Wan XB, Wang AQ, Cao J, Dong ZC, Li N, Yang S, Sun MM, Li Z, Luo SX.
    World J Gastroenterol; 2019 Feb 21; 25(7):808-823. PubMed ID: 30809081
    [Abstract] [Full Text] [Related]

  • 2. Mutation Status and Prognostic Value of KRAS and BRAF in Southeast Iranian Colorectal Cancer Patients: First Report from Southeast of Iran.
    Yari A, Samoudi A, Afzali A, Karam ZM, Karimaldini NK, Abadi MFS, Ziasistani M, Zangouey MR, Dabiri S.
    J Gastrointest Cancer; 2021 Jun 21; 52(2):557-568. PubMed ID: 32495109
    [Abstract] [Full Text] [Related]

  • 3. Concomitant dysregulation of the estrogen receptor and BRAF/MEK signaling pathways is common in colorectal cancer and predicts a worse prognosis.
    Liu D.
    Cell Oncol (Dordr); 2019 Apr 21; 42(2):197-209. PubMed ID: 30645729
    [Abstract] [Full Text] [Related]

  • 4. KRAS and PIK3CA mutations in colorectal adenocarcinomas correlate with aggressive histological features and behavior.
    Jang S, Hong M, Shin MK, Kim BC, Shin HS, Yu E, Hong SM, Kim J, Chun SM, Kim TI, Choi KC, Ko YW, Kim JW.
    Hum Pathol; 2017 Jul 21; 65():21-30. PubMed ID: 28188750
    [Abstract] [Full Text] [Related]

  • 5. RAS/RAF mutations and their associations with epigenetic alterations for distinct pathways in Vietnamese colorectal cancer.
    Ta TV, Nguyen QN, Chu HH, Truong VL, Vuong LD.
    Pathol Res Pract; 2020 Apr 21; 216(4):152898. PubMed ID: 32089414
    [Abstract] [Full Text] [Related]

  • 6. [Mutations of KRAS and BRAF in Chinese patients with colorectal carcinoma: analyses of 966 cases].
    Gao J, Sun ZW, Li YY, Shen L.
    Zhonghua Bing Li Xue Za Zhi; 2012 Sep 21; 41(9):579-83. PubMed ID: 23157823
    [Abstract] [Full Text] [Related]

  • 7. Localization of active, dually phosphorylated extracellular signal-regulated kinase 1 and 2 in colorectal cancer with or without activating BRAF and KRAS mutations.
    Holck S, Bonde J, Pedersen H, Petersen AA, Chaube A, Nielsen HJ, Larsson LI.
    Hum Pathol; 2016 Aug 21; 54():37-46. PubMed ID: 27036313
    [Abstract] [Full Text] [Related]

  • 8. Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy.
    Llovet P, Sastre J, Ortega JS, Bando I, Ferrer M, García-Alfonso P, Donnay O, Carrato A, Jiménez A, Aranda E, León A, Grávalos C, Cámara JC, Feliú J, Sanchíz B, Caldés T, Díaz-Rubio E.
    Mol Diagn Ther; 2015 Dec 21; 19(6):397-408. PubMed ID: 26341080
    [Abstract] [Full Text] [Related]

  • 9. Correlations of IGF-1R and COX-2 Expressions with Ras and BRAF Genetic Mutations, Clinicopathological Features and Prognosis of Colorectal Cancer Patients.
    Jin M, Long ZW, Yang J, Lin X.
    Pathol Oncol Res; 2018 Jan 21; 24(1):45-57. PubMed ID: 28188432
    [Abstract] [Full Text] [Related]

  • 10. Detection of MAPK/ERK pathway proteins and KRAS mutations in adenomatoid odontogenic tumors.
    Bologna-Molina R, Ogawa I, Mosqueda-Taylor A, Takata T, Sánchez-Romero C, Villarroel-Dorrego M, Takeda Y, Mikami T.
    Oral Dis; 2019 Mar 21; 25(2):481-487. PubMed ID: 30294831
    [Abstract] [Full Text] [Related]

  • 11. Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.
    Seth R, Crook S, Ibrahem S, Fadhil W, Jackson D, Ilyas M.
    Gut; 2009 Sep 21; 58(9):1234-41. PubMed ID: 19474002
    [Abstract] [Full Text] [Related]

  • 12. Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers.
    Temraz S, Mukherji D, Shamseddine A.
    Int J Mol Sci; 2015 Sep 23; 16(9):22976-88. PubMed ID: 26404261
    [Abstract] [Full Text] [Related]

  • 13. KRAS(G12D)- and BRAF(V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling.
    Appleman VA, Ahronian LG, Cai J, Klimstra DS, Lewis BC.
    Mol Cancer Res; 2012 Sep 23; 10(9):1228-39. PubMed ID: 22871572
    [Abstract] [Full Text] [Related]

  • 14. BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis.
    Nam SK, Yun S, Koh J, Kwak Y, Seo AN, Park KU, Kim DW, Kang SB, Kim WH, Lee HS.
    PLoS One; 2016 Sep 23; 11(3):e0151865. PubMed ID: 26991109
    [Abstract] [Full Text] [Related]

  • 15. Concomitant RAS and BRAF mutation in colorectal cancer - A report of 7 cases.
    Ates O, Yalcin S.
    Indian J Cancer; 2019 Sep 23; 56(2):176-179. PubMed ID: 31062740
    [Abstract] [Full Text] [Related]

  • 16. Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation.
    Lee S, Cho NY, Choi M, Yoo EJ, Kim JH, Kang GH.
    Pathol Int; 2008 Feb 23; 58(2):104-13. PubMed ID: 18199160
    [Abstract] [Full Text] [Related]

  • 17. High Concordance and Negative Prognostic Impact of RAS/BRAF/PIK3CA Mutations in Multiple Resected Colorectal Liver Metastases.
    Brunsell TH, Sveen A, Bjørnbeth BA, Røsok BI, Danielsen SA, Brudvik KW, Berg KCG, Johannessen B, Cengija V, Abildgaard A, Guren MG, Nesbakken A, Lothe RA.
    Clin Colorectal Cancer; 2020 Mar 23; 19(1):e26-e47. PubMed ID: 31982351
    [Abstract] [Full Text] [Related]

  • 18. mTORC1 upregulation via ERK-dependent gene expression change confers intrinsic resistance to MEK inhibitors in oncogenic KRas-mutant cancer cells.
    Komatsu N, Fujita Y, Matsuda M, Aoki K.
    Oncogene; 2015 Nov 05; 34(45):5607-16. PubMed ID: 25703330
    [Abstract] [Full Text] [Related]

  • 19. BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients.
    Chen J, Guo F, Shi X, Zhang L, Zhang A, Jin H, He Y.
    BMC Cancer; 2014 Nov 03; 14():802. PubMed ID: 25367198
    [Abstract] [Full Text] [Related]

  • 20. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
    Vakana E, Pratt S, Blosser W, Dowless M, Simpson N, Yuan XJ, Jaken S, Manro J, Stephens J, Zhang Y, Huber L, Peng SB, Stancato LF.
    Oncotarget; 2017 Feb 07; 8(6):9251-9266. PubMed ID: 27999210
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 128.